๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan

โœ Scribed by Alexander Liede; Imtiaz A. Malik; Zeba Aziz; Patricia de los Rios; Elaine Kwan; Steven A. Narod

Book ID
117853998
Publisher
American Society of Human Genetics
Year
2002
Tongue
English
Weight
182 KB
Volume
71
Category
Article
ISSN
0002-9297

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Contribution of BRCA1 and BRCA2 mutation
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
โœ Susan J. Ramus; Patricia A. Harrington; Carole Pye; Richard A. DiCioccio; Mark J ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 403 KB

A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (

Prevalence of BRCA1 and BRCA2 mutations
Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients
โœ Muhammad U. Rashid; Anbreen Zaidi; Diana Torres; Faisal Sultan; Axel Benner; Bil ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 312 KB ๐Ÿ‘ 2 views

## Abstract Among Asian countries, Pakistan has the highest rates of breast and ovarian cancer. To assess the contribution of the __BRCA1__ and __BRCA2__ germ line mutations to these high rates, we conducted the first study of 176 Pakistani breast and ovarian cancer patients, selected on family his

BRCA1 and BRCA2 mutations in breast/ovar
BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy
โœ L. Stuppia; P. Di Fulvio; G. Aceto; S. Pintor; S. Veschi; V. Gatta; A. Colosimo; ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 2 views

We report on the screening of the entire BRCA1/BRCA2 coding sequence by SSCP, PTT, and direct sequencing in 68 Italian families with recurrent breast or ovarian cancer. For each investigated proband, the probability of being carrier of a BRCA1/BRCA2 mutation was evaluated using the BRCAPRO software.